 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 January 1995 | Volume 122 Issue 1 | Pages 9-16
Objective: To determine the relation between estrogen replacement therapy and fractures.
Design: Prospective cohort study.
Setting: Four clinical centers in Baltimore County, Maryland; Minneapolis, Minnesota; Portland, Oregon; and the Monongahela Valley, Pennsylvania.
Participants: 9704 ambulatory, nonblack women 65 years of age or older.
Measurements: Estrogen use, medical history, and anthropometric data were obtained by questionnaire, interview, and examination. Appendicular bone mass was measured by single-photon absorptiometry. Incident fractures were validated by radiographic report.
Results: After adjustment for potential confounders, current estrogen use was associated with a decrease in the risk for wrist fractures (relative risk [RR], 0.39; 95% CI, 0.24 to 0.64) and for all nonspinal fractures (RR, 0.66; CI, 0.54 to 0.80) when compared with no estrogen use. Results were similar for women using unopposed estrogen or estrogen plus progestin, for women younger or older than 75 years of age, and for current smokers or nonsmokers. The effect of estrogen remained after adjustment was made for appendicular bone mass. The relative risk for hip fracture tended to be lower among current users (RR, 0.60; CI, 0.36 to 1.02) than among never-users. Estrogen was most effective in preventing hip fracture among those older than 75 years. Current users who started estrogen within 5 years of menopause had a decreased risk for hip fractures (RR, 0.29; CI, 0.09 to 0.92), wrist fractures (RR, 0.29; CI, 0.13 to 0.68), and all nonspinal fractures (RR, 0.50; CI, 0.36 to 0.70) when compared with women who had never used estrogen. Previous use of estrogen for more than 10 years or use begun soon after menopause had no substantial effect on the risk for fractures.
Conclusions: Current use of estrogen appears to decrease the risk for fracture in older women. These results suggest that for protection against fractures, estrogen should be initiated soon after menopause and continued indefinitely.
*For members of the Study of Osteoporotic Fractures Research Group, see the Appendix.
Author and Article Information
From the University of Pittsburgh, Pittsburgh, Pennsylvania; University of California at San Francisco, San Francisco, California; Veterans Affairs Medical Center and University of Minnesota, Minneapolis, Minnesota; and the Kaiser Permanente Medical Care Program, Oakland, California.
ARTICLE
Estrogen Replacement Therapy and Fractures in Older Women
Requests for Reprints: Jane A. Cauley, DrPH, A524 Crabtree Hall, Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA 15261.
Acknowledgments: The authors thank Ms. Amy Horner for preparing the manuscript.
Grant Support: In part by Public Health Service grants 1-R01-AR35582, 1-R01-AG05395, 1-R01-AM35584, 1-R01-AR35583, and 1-R01-AG05407.
This article has been cited by other articles:
|
|
 |
|
  D.B. Kimmel Mechanism of Action, Pharmacokinetic and Pharmacodynamic Profile, and Clinical Applications of Nitrogen-containing Bisphosphonates J. Dent. Res., November 1, 2007; 86(11): 1022 - 1033. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. D. Sloane, A. L. Gruber-Baldini, S. Zimmerman, M. Roth, L. Watson, M. Boustani, J. Magaziner, and J. R. Hebel Medication Undertreatment in Assisted Living Settings Arch Intern Med, October 11, 2004; 164(18): 2031 - 2037. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Osteoporosis Obstet. Gynecol., October 1, 2004; 104(4_suppl): 66S - 76S. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Banks, V. Beral, G. Reeves, A. Balkwill, and I. Barnes Fracture Incidence in Relation to the Pattern of Use of Hormone Therapy in Postmenopausal Women JAMA, May 12, 2004; 291(18): 2212 - 2220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The Women's Health Initiative Steering Committee Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial JAMA, April 14, 2004; 291(14): 1701 - 1712. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Z. Ke, G. L. Foley, H. A. Simmons, V. Shen, and D. D. Thompson Long-Term Treatment of Lasofoxifene Preserves Bone Mass and Bone Strength and Does Not Adversely Affect the Uterus in Ovariectomized Rats Endocrinology, April 1, 2004; 145(4): 1996 - 2005. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Armstrong, J. S. Schwartz, T. Randall, S. C. Rubin, and B. Weber Hormone Replacement Therapy and Life Expectancy After Prophylactic Oophorectomy in Women With BRCA1/2 Mutations: A Decision Analysis J. Clin. Oncol., March 15, 2004; 22(6): 1045 - 1054. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Evio, A. Tiitinen, K. Laitinen, O. Ylikorkala, and M. J. Valimaki Effects of Alendronate and Hormone Replacement Therapy, Alone and in Combination, on Bone Mass and Markers of Bone Turnover in Elderly Women with Osteoporosis J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 626 - 631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A J Lee, P Mitchell, E Rochtchina, and P R Healey Female reproductive factors and open angle glaucoma: the Blue Mountains Eye Study Br. J. Ophthalmol., November 1, 2003; 87(11): 1324 - 1328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Cauley, J. Robbins, Z. Chen, S. R. Cummings, R. D. Jackson, A. Z. LaCroix, M. LeBoff, C. E. Lewis, J. McGowan, J. Neuner, et al. Effects of Estrogen Plus Progestin on Risk of Fracture and Bone Mineral Density: The Women's Health Initiative Randomized Trial JAMA, October 1, 2003; 290(13): 1729 - 1738. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Prestwood, A. M. Kenny, A. Kleppinger, and M. Kulldorff Ultralow-Dose Micronized 17{beta}-Estradiol and Bone Density and Bone Metabolism in Older Women: A Randomized Controlled Trial JAMA, August 27, 2003; 290(8): 1042 - 1048. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B.J. van Meurs, S. C.E. Schuit, A. E.A.M. Weel, M. van der Klift, A. P. Bergink, P. P. Arp, E. M. Colin, Y. Fang, A. Hofman, C. M. van Duijn, et al. Association of 5' estrogen receptor alpha gene polymorphisms with bone mineral density, vertebral bone area and fracture risk Hum. Mol. Genet., July 15, 2003; 12(14): 1745 - 1754. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. L. Ma, H. U. Bryant, Q. Zeng, A. Schmidt, J. Hoover, H. W. Cole, W. Yao, W. S. S. Jee, and M. Sato New Bone Formation with Teriparatide [Human Parathyroid Hormone-(1-34)] Is Not Retarded by Long-Term Pretreatment with Alendronate, Estrogen, or Raloxifene in Ovariectomized Rats Endocrinology, May 1, 2003; 144(5): 2008 - 2015. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. F Eichner, K. B Lloyd, and E. M Timpe Comparing Therapies for Postmenopausal Osteoporosis Prevention and Treatment Ann. Pharmacother., May 1, 2003; 37(5): 711 - 724. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Sagraves Evaluating Therapeutic Modalities for Prevention and Treatment of Postmenopausal Osteoporosis Ann. Pharmacother., May 1, 2003; 37(5): 744 - 746. [Full Text] [PDF]
|
|
|
|
|
|
B. H. Ascott-Evans, N. Guanabens, S. Kivinen, B. G. A. Stuckey, C. H. Magaril, K. Vandormael, B. Stych, and M. E. Melton Alendronate Prevents Loss of Bone Density Associated With Discontinuation of Hormone Replacement Therapy: A Randomized Controlled Trial Arch Intern Med, April 14, 2003; 163(7): 789 - 794. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Figueroa, S. B. Going, L. A. Milliken, R. M. Blew, S. Sharp, P. J. Teixeira, and T. G. Lohman Effects of Exercise Training and Hormone Replacement Therapy on Lean and Fat Mass in Postmenopausal Women J. Gerontol. A Biol. Sci. Med. Sci., March 1, 2003; 58(3): M266 - 270. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. T. Levy, J. M. Ritchie, E. Smith, T. Gray, and W. Zhang Physician Specialty Is Significantly Associated With Hormone Replacement Therapy Use Obstet. Gynecol., January 1, 2003; 101(1): 114 - 122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Greenspan, R. D. Emkey, H. G. Bone III, S. R. Weiss, N. H. Bell, R. W. Downs Jr., C. McKeever, S. S. Miller, M. Davidson, M. A. Bolognese, et al. Significant Differential Effects of Alendronate, Estrogen, or Combination Therapy on the Rate of Bone Loss after Discontinuation of Treatment of Postmenopausal Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled Trial Ann Intern Med, December 3, 2002; 137(11): 875 - 883. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. D. Nelson, J. Rizzo, E. Harris, J. Cauley, K. Ensrud, D. C. Bauer, E. Orwoll, and for the Study of Osteoporotic Fractures Research G Osteoporosis and Fractures in Postmenopausal Women Using Estrogen Arch Intern Med, November 11, 2002; 162(20): 2278 - 2284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Gallagher, P. B. Rapuri, G. Haynatzki, and J. R. Detter Effect of Discontinuation of Estrogen, Calcitriol, and the Combination of Both on Bone Density and Bone Markers J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 4914 - 4923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Cummings, D. Bates, and D. M. Black Clinical Use of Bone Densitometry: Scientific Review JAMA, October 16, 2002; 288(15): 1889 - 1897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. D. Nelson, L. L. Humphrey, P. Nygren, S. M. Teutsch, and J. D. Allan Postmenopausal Hormone Replacement Therapy: Scientific Review JAMA, August 21, 2002; 288(7): 872 - 881. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Gardner, K. R. Flik, P. Mooar, and J. M. Lane Improvement in the Undertreatment of Osteoporosis Following Hip Fracture J. Bone Joint Surg. Am., August 12, 2002; 84(8): 1342 - 1348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Wells, P. Tugwell, B. Shea, G. Guyatt, J. Peterson, N. Zytaruk, V. Robinson, D. Henry, D. O'Connell, and A. Cranney V. Meta-Analysis of the Efficacy of Hormone Replacement Therapy in Treating and Preventing Osteoporosis in Postmenopausal Women Endocr. Rev., August 1, 2002; 23(4): 529 - 539. [Full Text] [PDF]
|
|
|
|
|
|
A. Cranney, G. Guyatt, L. Griffith, G. Wells, P. Tugwell, and C. Rosen IX: Summary of Meta-Analyses of Therapies for Postmenopausal Osteoporosis Endocr. Rev., August 1, 2002; 23(4): 570 - 578. [Full Text] [PDF]
|
|
|
|
|
|
N. S. Weiss and M. M. Treggiari Postmenopausal Hormone Use and Skeletal Fracture: Does the Size of the Benefit Decrease With Increasing Age? Obstet. Gynecol., August 1, 2002; 100(2): 364 - 368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hulley, C. Furberg, E. Barrett-Connor, J. Cauley, D. Grady, W. Haskell, R. Knopp, M. Lowery, S. Satterfield, H. Schrott, et al. Noncardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy: Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II) JAMA, July 3, 2002; 288(1): 58 - 64. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Grady A 60-Year-Old Woman Trying to Discontinue Hormone Replacement Therapy JAMA, April 24, 2002; 287(16): 2130 - 2137. [Full Text] [PDF]
|
|
|
|
|
|
S. Palomba, F. Orio Jr., A. Colao, C. di Carlo, T. Sena, G. Lombardi, F. Zullo, and P. Mastrantonio Effect of Estrogen Replacement Plus Low-Dose Alendronate Treatment on Bone Density in Surgically Postmenopausal Women with Osteoporosis J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1502 - 1508. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Greendale, M. Espeland, S. Slone, R. Marcus, E. Barrett-Connor, and for the PEPI Safety Follow-up Study Investigators Bone Mass Response to Discontinuation of Long-term Hormone Replacement Therapy: Results From the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study Arch Intern Med, March 25, 2002; 162(6): 665 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Marcus, M. Wong, H. Heath III, and J. L. Stock Antiresorptive Treatment of Postmenopausal Osteoporosis: Comparison of Study Designs and Outcomes in Large Clinical Trials with Fracture as an Endpoint Endocr. Rev., February 1, 2002; 23(1): 16 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Gehlbach, M. Fournier, and C. Bigelow Recognition of Osteoporosis by Primary Care Physicians Am J Public Health, February 1, 2002; 92(2): 271 - 273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. SHERMAN Preventing and Treating Osteoporosis: Strategies at the Millennium Ann. N.Y. Acad. Sci., December 1, 2001; 949(1): 188 - 197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. ANTHONY, J. K. WILLIAMS, and B. K. DUNN What Would Be the Properties of an Ideal SERM? Ann. N.Y. Acad. Sci., December 1, 2001; 949(1): 261 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Cauley, J. M. Zmuda, K. E. Ensrud, D. C. Bauer, and B. Ettinger Timing of Estrogen Replacement Therapy for Optimal Osteoporosis Prevention J. Clin. Endocrinol. Metab., December 1, 2001; 86(12): 5700 - 5705. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Grossman and C. H. MacLean Quality Indicators for the Management of Osteoporosis in Vulnerable Elders Ann Intern Med, October 16, 2001; 135(8_Part_2): 722 - 730. [Full Text] [PDF]
|
|
|
|
 |
|
 U. Schobel, M. Frenay, D. A. Van Elswijk, J. M. McAndrews, K. R. Long, L. M. Olson, S. C. Bobzin, and H. Irth High Resolution Screening of Plant Natural Product Extracts for Estrogen Receptor a and f3 Binding Activity Using an Online HPLC-MS Biochemical Detection System J Biomol Screen, October 1, 2001; 6(5): 291 - 303. [Abstract] [PDF]
|
|
|
|
|
|
D. T. Villareal, E. F. Binder, D. B. Williams, K. B. Schechtman, K. E. Yarasheski, and W. M. Kohrt Bone Mineral Density Response to Estrogen Replacement in Frail Elderly Women: A Randomized Controlled Trial JAMA, August 15, 2001; 286(7): 815 - 820. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. I. Pritchard Hormone Replacement in Women with a History of Breast Cancer Oncologist, August 1, 2001; 6(4): 353 - 362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Wade Rheumatology: 15. Osteoporosis Can. Med. Assoc. J., July 1, 2001; 165(1): 45 - 50. [Full Text] [PDF]
|
|
|
|
|
|
D. J. Torgerson and S. E. M. Bell-Syer Hormone Replacement Therapy and Prevention of Nonvertebral Fractures: A Meta-analysis of Randomized Trials JAMA, June 13, 2001; 285(22): 2891 - 2897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Grady and S. R. Cummings Postmenopausal Hormone Therapy for Prevention of Fractures: How Good Is the Evidence? JAMA, June 13, 2001; 285(22): 2909 - 2910. [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Newcomb, A. Trentham-Dietz, K. M. Egan, L. Titus-Ernstoff, J. A. Baron, B. E. Storer, W. C. Willett, and M. J. Stampfer Fracture History and Risk of Breast and Endometrial Cancer Am. J. Epidemiol., June 1, 2001; 153(11): 1071 - 1078. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Baron, B. Y. Farahmand, E. Weiderpass, K. Michaelsson, A. Alberts, I. Persson, and S. Ljunghall Cigarette Smoking, Alcohol Consumption, and Risk of Hip Fracture in Women Arch Intern Med, April 9, 2001; 161(7): 983 - 988. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Yosipovitch, T. S. Hoon, and G. C. Leok Suggested Rationale for Prevention and Treatment of Glucocorticoid-Induced Bone Loss in Dermatologic Patients Arch Dermatol, April 1, 2001; 137(4): 477 - 481. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Altkorn and T. Vokes Treatment of Postmenopausal Osteoporosis JAMA, March 21, 2001; 285(11): 1415 - 1418. [Full Text] [PDF]
|
|
|
|
|
|
J. H. Tobias, S. Clarke, K. Mitchell, S. Robins, H. Amer, and W. D. Fraser Analysis of the Contribution of Dydrogesterone to Bone Turnover Changes in Postmenopausal Women Commencing Hormone Replacement Therapy J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1194 - 1198. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. R. McClung, P. Geusens, P. D. Miller, H. Zippel, W. G. Bensen, C. Roux, S. Adami, I. Fogelman, T. Diamond, R. Eastell, et al. Effect of Risedronate on the Risk of Hip Fracture in Elderly Women N. Engl. J. Med., February 1, 2001; 344(5): 333 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Prestwood, A. M. Kenny, C. Unson, and M. Kulldorff The Effect of Low Dose Micronized 17{beta}-Estradiol on Bone Turnover, Sex Hormone Levels, and Side Effects in Older Women: A Randomized, Double Blind, Placebo-Controlled Study J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4462 - 4469. [Abstract] [Full Text]
|
|
|
|
|
|
P. LOPES, H. M. W. M. MERKUS, J. NAUMAN, F. BRUSCHI, J.-M. FOIDART, and J. CALAF Randomized Comparison of Intranasal and Transdermal Estradiol Obstet. Gynecol., December 1, 2000; 96(6): 906 - 912. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A Donker, P. Spreeuwenberg, A. I. Bartelds, K. van der Velden, and M. Foets Hormone replacement therapy: changes in frequency and type of prescription by Dutch GPs during the last decade of the millennium Fam. Pract., December 1, 2000; 17(6): 508 - 513. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Mosca The Role of Hormone Replacement Therapy in the Prevention of Postmenopausal Heart Disease Arch Intern Med, August 14, 2000; 160(15): 2263 - 2272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. B. Freedman, F. S. Kaplan, W. B. Bilker, B. L. Strom, and R. A. Lowe Treatment of Osteoporosis: Are Physicians Missing an Opportunity?*{{dagger}} J. Bone Joint Surg. Am., August 1, 2000; 82(8): 1063 - 1063. [Abstract] [Full Text]
|
|
|
|
|
|
K. M. Prestwood, M. Gunness, D. B. Muchmore, Y. Lu, M. Wong, and L. G. Raisz A Comparison of the Effects of Raloxifene and Estrogen on Bone in Postmenopausal Women J. Clin. Endocrinol. Metab., June 1, 2000; 85(6): 2197 - 2202. [Abstract] [Full Text]
|
|
|
|
|
|
I. Fogelman, C. Ribot, R. Smith, D. Ethgen, E. Sod, and J.-Y. Reginster Risedronate Reverses Bone Loss in Postmenopausal Women with Low Bone Mass: Results From a Multinational, Double-Blind, Placebo-Controlled Trial J. Clin. Endocrinol. Metab., May 1, 2000; 85(5): 1895 - 1900. [Abstract] [Full Text]
|
|
|
|
|
|
J. Yates, E. Barrett-Connor, S. Barlas, Y.-T. Chen, P. D. Miller, and E. S. Siris Rapid Loss of Hip Fracture Protection After Estrogen Cessation: Evidence From the National Osteoporosis Risk Assessment Obstet. Gynecol., January 1, 2000; 103(3): 440 - 446. [Abstract] [Full Text]
|
|
|
|
 |
|
 E M Scott, I Gaywood, and B B Scott Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease Gut, January 1, 2000; 46(90001): I1 - 8. [Full Text] [PDF]
|
|
|
|
 |
|
 G. W. de Valk-de Roo, C. D.A. Stehouwer, P. Meijer, V. Mijatovic, C. Kluft, P. Kenemans, F. Cohen, S. Watts, and C. Netelenbos Both Raloxifene and Estrogen Reduce Major Cardiovascular Risk Factors in Healthy Postmenopausal Women : A 2-Year, Placebo-Controlled Study Arterioscler. Thromb. Vasc. Biol., December 1, 1999; 19(12): 2993 - 3000. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Article
